Insider Transactions in Q4 2023 at Neurocrine Biosciences Inc (NBIX)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 22
2023
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-33.87%
|
$1,260,000
$126.74 P/Share
|
|
Dec 22
2023
|
Gary A Lyons Director |
SELL
Open market or private sale
|
Direct |
10,000
-4.91%
|
$1,300,000
$130.04 P/Share
|
|
Dec 22
2023
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
24,000
-40.73%
|
$3,072,000
$128.39 P/Share
|
|
Dec 22
2023
|
Julie Cooke Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+28.88%
|
$1,704,000
$71.44 P/Share
|
|
Dec 12
2023
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,925
-19.08%
|
$1,671,000
$120.31 P/Share
|
|
Dec 12
2023
|
Eiry Roberts Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,925
+16.03%
|
$1,127,925
$81.05 P/Share
|
|
Dec 08
2023
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
300
-0.51%
|
$36,000
$120.08 P/Share
|
|
Dec 08
2023
|
Eiry Roberts Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+0.5%
|
$24,300
$81.05 P/Share
|
|
Dec 07
2023
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
77,379
-36.95%
|
$9,285,480
$120.37 P/Share
|
|
Dec 07
2023
|
Eiry Roberts Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
77,379
+26.5%
|
$6,035,562
$78.92 P/Share
|
|
Dec 06
2023
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,396
-22.14%
|
$1,007,520
$120.03 P/Share
|
|
Dec 06
2023
|
Eiry Roberts Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,396
+18.13%
|
$646,492
$77.81 P/Share
|
|
Dec 06
2023
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
20,830
-36.73%
|
$2,478,770
$119.86 P/Share
|
|
Dec 06
2023
|
Darin Lippoldt Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,830
+26.86%
|
$895,690
$43.24 P/Share
|
|
Dec 01
2023
|
Gary A Lyons Director |
SELL
Open market or private sale
|
Direct |
5,000
-2.4%
|
$580,000
$116.77 P/Share
|
|
Dec 01
2023
|
Gary A Lyons Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.34%
|
$60,000
$12.98 P/Share
|
|
Nov 29
2023
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,331
-16.58%
|
$263,403
$113.57 P/Share
|
|
Nov 27
2023
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,919
-23.33%
|
$1,222,928
$112.27 P/Share
|
|
Nov 16
2023
|
Stephen A Sherwin Director |
SELL
Bona fide gift
|
Direct |
2,750
-10.98%
|
-
|
|
Oct 02
2023
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
1,437
-22.7%
|
$160,944
$112.68 P/Share
|